1-4 of 4
Hsu-Ping Kuo
Close
Sort by
Journal Articles

Ibrutinib Potentiated NK Cell-Mediated Cytotoxicity in Mouse Models of B-Cell Lymphomas

Hsu-Ping Kuo, PhD, Sidney Hsieh, MSc, Jennifer Whang, PhD, Yujun Huang, PhD, Mint Sirisawad, BS, Betty Y. Chang, PhD
Journal: Blood
Blood (2016) 128 (22): 4140.
https://doi.org/10.1182/blood.V128.22.4140.4140
Published: 2016
Journal Articles

Mutation Impact of Targeted Genes in Diffuse Large B-Cell Lymphoma Patients Treated with Ibrutinib

Leo WK Cheung, Karl J. Schweighofer, Shiquan Wu, Hsu-Ping Kuo, Karl Eckert, Sriram Balasubramanian, PhD, Deborah Ricci, Yu Liang, Darrin Beaupre, Betty Y. Chang
Journal: Blood
Blood (2015) 126 (23): 2642.
https://doi.org/10.1182/blood.V126.23.2642.2642
Published: 2015
Journal Articles

The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma

Hsu-Ping Kuo, Sidney Hsieh, Karl J. Schweighofer, Leo WK Cheung, Shiquan Wu, Mutiah Apatira, Mint Sirisawad, Karl Eckert, Yu Liang, Jeff Hsu, Betty Y. Chang, PhD
Journal: Blood
Blood (2015) 126 (23): 699.
https://doi.org/10.1182/blood.V126.23.699.699
Published: 2015
Journal Articles

Combination of Ibrutinib and BCL-2 or SYK Inhibitors in Ibrutinib Resistant ABC-Subtype of Diffuse Large B-Cell Lymphoma

Hsu-Ping Kuo, Richard Crowley, Ling Xue, Karl J. Schweighofer, Leo WK. Cheung, Sidney Hsieh, Karl Eckert, BA, Matthias Versele, Betty Y. Chang
Journal: Blood
Blood (2014) 124 (21): 505.
https://doi.org/10.1182/blood.V124.21.505.505
Published: 2014